Inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), is an increasingly common immune-mediated disease of the gut of unknown cause.[@bib1; @bib2] The genetic architecture of IBD is complex, with more than 130 significantly associated susceptibility loci identified to date,[@bib3] indicating that multiple mechanisms of disease may exist. Nevertheless, prominent roles for innate immunity and particular immune response pathways, including the interleukin (IL) 23/IL17 axis, strongly are implicated.

Innate lymphoid cells (ILCs) are emerging as important players in mucosal immunity. Although recognized to perform protective roles against mucosal pathogens,[@bib4; @bib5] they also contribute to chronic intestinal inflammation, which is particularly apparent in mice lacking conventional T and B cells.[@bib6; @bib7] This is in part dependent on their capacity to produce inflammatory cytokines, including interferon-γ, IL17A, and IL22.[@bib4; @bib5; @bib6; @bib7; @bib8] ILCs can be subdivided into discrete populations, which accumulate in mucosal tissues in different pathologic settings.[@bib9] At least 3 subsets exist, including ILC1s, which produce interferon-γ; ILC2s, which produce IL5/IL13; and ILC3, which can be subdivided further based on differential expression of natural cytotoxicity receptors (NCRs), CD4, and production of IL17 and/or IL22.[@bib9]

*Tbx21*^*-/-*^ *Rag2*^*-/-*^ ulcerative colitis (TRUC) mice spontaneously develop severe colitis with striking similarities to some aspects of human UC.[@bib10] Colon lesions histologically resemble UC with goblet cell depletion, crypt abscess formation, epithelial hyperplasia, and infiltration of colonic lamina propria with neutrophils and mononuclear cells.[@bib7; @bib10] TRUC mice develop inflammation-associated epithelial dysplasia, which frequently progresses to frank adenocarcinoma,[@bib11] one of the most severe complications in human forms of IBD. TRUC disease is dependent on interactions between intestinal CD11c^+^ mononuclear phagocytes and CD90^+^ IL7R-receptor--positive (IL7R^+^) ILCs.[@bib7] Depletion of ILCs or genetic deficiency of the common γ-chain cytokine receptor, which is necessary for ILC survival, prevents disease.[@bib7] Similarly, blockade of IL23 or IL17A significantly attenuates disease.[@bib7] ILCs accumulate in gut lesions from IBD patients[@bib12; @bib13; @bib14] and it has been speculated that targeting these cells might represent a viable therapeutic approach in IBD.[@bib15] IL23[@bib6; @bib7] and IL1β[@bib16] contribute to ILC activation, although curiously TRUC mice that additionally are deficient for either IL23R or IL1R are not fully protected from colitis,[@bib17] consistent with a possible role for alternative ILC activation pathways contributing to disease. The purpose of this study was to investigate the proximal signals responsible for driving intestinal ILC activation and to determine whether similar pathways might exist in human disease.

Materials and Methods {#sec1}
=====================

Mice {#sec1.1}
----

Balb/C *Rag2*^-/-^ and wild-type mice were sourced commercially (Jackson Laboratories; Bar Harbor, ME). TRUC mice were a gift from Laurie Glimcher. Animal experiments were performed in accredited facilities in accordance with the UK Animals (Scientific Procedures) Act 1986 (Home Office License Number PPL: 70/6792 and PPL: 70/7869 from November 2013).

Human Studies {#sec1.2}
-------------

Studies in human tissues received ethical approval from the City and Hackney Local Research Ethics Committee (REC reference: 10/H0704/74 and 10/H0804/65). Colonic lamina propria mononuclear cells (cLPMCs) were isolated as described previously[@bib18] from colectomy specimens and endoscopically acquired biopsy specimens. Normal colonic mucosal samples were collected from macroscopically unaffected areas of patients undergoing intestinal resection for colon cancer or polyps. Informed written consent was obtained in all cases.

Flow Cytometry and Cell Sorting {#sec1.3}
-------------------------------

Intracellular cytokine expression was measured as described previously.[@bib7] Cells were stimulated with IL23 (10--20 ng/mL), IL6 (10--100 ng/mL), or phorbol 12-myristate 13-acetate (PMA) (50 ng/mL) and ionomycin (1 μmol/L) for 4--6 hours at 37°C with monensin (3 μmol/L) added for the last 2 hours. In human work, antibodies used to stain cell surface antigens were incubated with unstimulated cells for 25 minutes and then fixed in 2% paraformaldehyde pending analysis. For fluorescence-activated cell sorter purification of murine ILCs, CD45^+^ cells first were sorted immunomagnetically from unfractionated cLPMCs using anti-CD45 beads (Miltenyi) and LS columns (Miltenyi). CD45^+^ cells were stained with CD90, NKp46, and IL7R. Antibodies used in flow cytometry experiments are listed in [Supplementary Table 1](#tblS1){ref-type="table"}.

Ex Vivo Organ Culture {#sec1.4}
---------------------

Colon explants cultures from murine experiments were performed as described previously.[@bib7] Three biopsy punches from the distal colon were cultured in 500 μL of complete medium for 24 hours at 37°C. In human studies explant cultures were set up as described previously.[@bib18] Cytokine production in culture supernatants was measured by enzyme-linked immunosorbent assay (ELISA).

Cell Culture {#sec1.5}
------------

Unfractionated murine splenocytes (2 × 10^6^/mL) and mesenteric lymph node (mLN) cells (1 × 10^6^/mL) or cLPMCs (1 × 10^6^/mL) were cultured in complete medium for 24 hours at 37°C as described previously.[@bib7] cLPMCs from IBD and noninflammatory control patients were cultured with recombinant human IL6 (R&D) (0--100 ng/mL) overnight at 37°C, 5% CO~2~, and then restimulated with PMA (50 ng/mL) and ionomycin (1 μmol/L). In some experiments, cLPMCs were cultured with IL6 (100 ng/mL) for 6 hours in the presence of monensin (3 μmol/L). Fluorescence-activated cell sorter--purified NCR^-^ ILC3s (CD45^+^ CD90^+^ IL7R^+^ NKp46^-^) from TRUC mice were cultured at 5 × 10^4^/mL for 24 hours. Cytokine concentrations in culture supernatants were measured by ELISA (R&D Systems and eBioscience).

Histology {#sec1.6}
---------

Colon histology was processed, stained (H&E), and colitis scores were calculated as described previously.[@bib7] Proximal and distal colitis scores from individual mice were averaged, unless otherwise stated.

ELISA and Cytokine Bead Arrays {#sec1.7}
------------------------------

Cytokine concentrations were measured in culture supernatants by ELISA or T-helper cell (Th)1, Th2, or Th17 CBA (BD Biosciences).

Microarray and Real-Time Polymerase Chain Reaction {#sec1.8}
--------------------------------------------------

RNA was extracted from 3 *Rag2*^-/-^ and 3 TRUC mice, aged 10 weeks, using TRIzol reagent (Invitrogen Carlsbad, CA). Transcript expression was analyzed with Mouse Genome 430 2.0 Affymetrix Expression Array. For real-time polymerase chain reaction (PCR) experiments cells were lysed in TRIzol reagent (Invitrogen) and RNA was extracted. Complementary DNA was generated with the complementary DNA synthesis kit (Bioline, Taunton, MA). Quantitative PCR was used to quantify messenger RNA transcripts using TaqMan gene expression assays (Applied Biosystems). Gene expression was normalized to the expression of β-actin to generate ΔCT values and relative abundance was quantified using the 2^-ΔCT^ method. Human RORC (Hs01076112_m1) and β-actin (4326315E) TaqMan quantitative PCR primer sets were used.

In Vivo Antibody Treatment {#sec1.9}
--------------------------

Intraperitoneal injections of anti-CD4 (1 mg, GK1.5), anti-CD90 (1 mg, 30H12), anti-IL6 (750 μg, MP5-20F3), or isotype-matched control antibodies (LTF-2 or HRPN) (Bio X Cell, West Lebanon, NH) were administered on days 0, 7, 14, 21, and 28 (anti-CD4, anti-CD90) or days 0, 4, 9, 14, 18, 23, and 27 (anti-IL6).

Microbiota Analysis {#sec1.10}
-------------------

See the [Supplementary Materials and Methods](#appsec1){ref-type="sec"} section for more detail.

Results {#sec2}
=======

NCR^-^ CD4^-^ ILC3 Cells Are the Predominant Colonic ILC Subset in Chronic Intestinal Inflammation in TRUC Mice {#sec2.1}
---------------------------------------------------------------------------------------------------------------

We validated the phenotype of ILCs in TRUC mice, confirming excessive accumulation of IL17A- and IL22-producing CD90^+^ IL7R^+^ NCR^-^ ILC3 in diseased colons ([Figure 1](#fig1){ref-type="fig"}*A* and 1*B*, [Supplementary Figure 1](#figS1){ref-type="fig"}*A--D*). CD4-expressing NCR^-^ ILC3s resembling lymphoid tissue inducer cells participate in mucosal immune responses in the gut,[@bib5] therefore, we considered the possibility that CD4^+^ ILCs might be the NCR^-^ ILC3 subset responsible for mediating chronic inflammation in TRUC mice. CD4^+^ cells were present in mLNs of TRUC mice (many of which co-expressed CD90); however, very few CD4^+^ cells were present in the colon ([Figure 1](#fig1){ref-type="fig"}*C*). Given the low frequency of intestinal CD4^+^ ILCs in TRUC mice we considered it unlikely that these cells would play a major role in disease. To test this assumption we depleted CD4-expressing cells in vivo. The administration of anti-CD4 antibodies successfully depleted CD4-expressing cells in mLNs and colon of TRUC mice ([Figure 1](#fig1){ref-type="fig"}*C*). However, many CD90^+^ cells still remained in the colon and there was no reduction in the number of IL17A- or IL22-producing cells ([Figure 1](#fig1){ref-type="fig"}*D*). Depleting anti-CD4 treatment did not alter the severity of TRUC disease significantly ([Figure 1](#fig1){ref-type="fig"}*E*). In contrast, anti-CD90 treatment depleted both CD90- and CD4-expressing ILCs, reduced the number of IL17- and IL22-producing cells in the colon, and significantly attenuated disease ([Figure 1](#fig1){ref-type="fig"}*C--E*). Taken together, these data indicate IL17A/IL22 producing CD90^+^ IL7R^+^ NCR^-^ CD4^-^ ILC3 are the key ILC population in the colon responsible for causing disease in TRUC mice.

IL6 Is Expressed Highly and Augments Pathogenic Cytokine Production in TRUC Mice {#sec2.2}
--------------------------------------------------------------------------------

We sought to define the proximal immune signals responsible for triggering effector function of colonic NCR^-^ ILC3 in TRUC mice. IL1β and IL6 were among the most highly expressed (\>2-fold induction) cytokine transcripts in the colon of TRUC mice in comparison with *Rag2*^*-/-*^ mice ([Figure 2](#fig2){ref-type="fig"}*A*). The other IL1 family member, *Il1a*, and the IL23 subunit transcripts (*Il23a* and *Il12b*) also were increased. Proximal cytokines responsible for driving ILC1 (IL12, IL15, and IL18) or ILC2 (IL25 and IL33) responses were not up-regulated, and, indeed in most instances were down-regulated in the colon of TRUC mice in comparison with *Rag2*^*-/-*^ controls.

IL23 and IL1 have been described to play an important role triggering ILCs in TRUC disease, therefore, in this study we focussed our attention on IL6. In addition to increased *Il6* transcripts in the colon, there were very high concentrations of IL6 in serum and significantly increased production of IL6 in colon explant cultures from TRUC mice ([Supplementary Figure 2](#figS2){ref-type="fig"}*A*). Transcripts of genes known to be regulated by IL6[@bib19] were up-regulated in the colon of TRUC mice in comparison with *Rag2*^*-/-*^ controls ([Supplementary Figure 2](#figS2){ref-type="fig"}*B*), including well-recognized immune genes (*Socs1*, *Socs3*, and *Icam1*), IL6 signaling components (*Stat1* and *Stat3*), and anti-apoptotic genes (*Bcl3*, *Bcl6*, and *Bcl-x1*). The most highly expressed IL6-regulated gene in the colon of TRUC mice (12-fold enrichment) was *Pou2af1*, which encodes a transcriptional co-activator responsible for IL6-mediated regulation of IL17 responses in T cells.[@bib20]

To determine whether IL6 might trigger ILC-derived cytokines we stimulated unfractionated cLPMCs and mLN cells from TRUC mice with recombinant IL6. Strikingly, IL6 triggered IL17A production by both cLPMCs and mLN cells ([Figure 2](#fig2){ref-type="fig"}*B*). We also performed flow cytometry with intracellular cytokine staining after IL6 stimulation of unfractionated mLN cells. Although less potent than IL23, IL6 induced expression of IL17A in NCR^-^ ILC3s ([Figure 2](#fig2){ref-type="fig"}*C*). To determine whether this was a cell-intrinsic phenomenon we purified CD90^+^ IL7R^+^ NCR^-^ ILC3s from TRUC colons by fluorescence-activated cell sorting ([Supplementary Figure 3](#figS3){ref-type="fig"}*A*). To our surprise, neither IL6, IL23, nor IL1α by themselves induced significant cytokine production by purified colonic NCR^-^ ILC3s ([Figure 2](#fig2){ref-type="fig"}*D*). However, the combination of IL23 and IL1α was a potent trigger for ILC production of IL17A and IL22. The addition of IL6 together with IL23 and IL1α was the most potent trigger of all. Purified intestinal NCR^-^ ILCs from TRUC mice produced little tumor necrosis factor α or interferon-γ under these conditions ([Supplementary Figure 3](#figS3){ref-type="fig"}*B*). IL23 and IL1α were weak inducers of IL6 by colonic NCR^-^ ILCs ([Supplementary Figure 3](#figS3){ref-type="fig"}*B*). Taken together, these data showed that IL6 augments IL23/IL1α-induced pathogenic cytokine production by intestinal ILCs in TRUC mice in a cell-intrinsic manner.

IL6 signals through a heterodimeric receptor comprising ubiquitously expressed gp130 and selectively expressed IL6Rα. However, IL6Rα also exists as a soluble form, which can complex with IL6 in solution and then bind to cells expressing gp130, enabling cells, which do not usually express IL6Rα, to respond to IL6 stimulation. Therefore, we investigated IL6Rα and soluble IL6Rα (sIL6Rα) expression in TRUC mice. IL6Rα expression by ILCs was highly variable in the colon of TRUC mice, but typically was less than 10% ([Supplementary Figure 4](#figS4){ref-type="fig"}*A*, and data not shown). However, sIL6Rα was abundant in the serum of TRUC mice and was detected in supernatants from cultured colon explants and unfractionated splenocytes ([Supplementary Figure 4](#figS4){ref-type="fig"}*B*). Therefore, it is likely that ILCs respond to IL6 stimulation directly, but also potentially through trans-signaling given the abundance of sIL6R in TRUC mice.

IL6 Blockade Attenuated TRUC Disease Independently of Changes to Intestinal Microbiota Community Profiles {#sec2.3}
---------------------------------------------------------------------------------------------------------

To determine whether IL6-mediated activation of innate immunity was functionally important in TRUC disease, mice were treated with monoclonal antibodies that neutralize the biological activity of IL6. Treatment with anti-IL6 resulted in loss of IL6 bioavailability ([Supplementary Figure 5](#figS5){ref-type="fig"}*A*). IL17A production by unfractionated cLPMCs and splenocytes was reduced significantly in anti-IL6--treated TRUC mice, although was not abolished completely ([Figure 3](#fig3){ref-type="fig"}*A*). IL6 neutralization significantly attenuated TRUC disease, including reduced colitis scores and reduced splenomegaly ([Figure 3](#fig3){ref-type="fig"}*B* and *C*).

Similar to the situation in human IBD, TRUC disease is associated with perturbation of intestinal microbial communities. Because IL6 directly influences the success of mucosal colonization by some intestinal bacteria,[@bib21] we considered the possibility that attenuation of chronic TRUC disease after IL6 blockade might have occurred secondarily to changes in key components in the composition of the intestinal microbiota. To address this question we sequenced 16S ribosomal RNA genes that were PCR-amplified from fecal samples from anti-IL6 or control antibody--treated TRUC mice. Overall, we identified 2642 different operational taxonomic units (OTUs). Treatment with anti-IL6 antibody appeared to have a relatively minor impact on the microbiota ([Figure 4](#fig4){ref-type="fig"}*A*). At the phylum level, Firmicutes were reduced slightly in proportional abundance in anti-IL6--treated mice (*P* = .035) ([Figure 4](#fig4){ref-type="fig"}*A*) but, at finer taxonomic levels, anti-IL6 treatment did not impact the proportional abundance of the most common 150 OTUs significantly, which cumulatively accounted for more than 96% of the total amount of sequence data generated ([Supplementary Table 2](#tblS2){ref-type="table"}). Cluster analysis, using the Bray Curtis calculator, confirmed that there was no signature microbiota profile associated with anti-IL6 treatment ([Supplementary Figure 5](#figS5){ref-type="fig"}*B*). *Helicobacter typhlonius* was ubiquitously present in anti-IL6-- or isotype control--treated mice, however, the proportional abundance did not differ significantly between the 2 groups either before or after treatment ([Figure 4](#fig4){ref-type="fig"}*B*). There was a tendency for increased bacterial diversity in the gut of anti-IL6--treated mice in comparison with control antibody--treated mice, although this did not achieve statistical significance (*P* \< .095) ([Supplementary Figure 5](#figS5){ref-type="fig"}*C*).

IL6 Augments Pathogenic Cytokine Production by Colonic CD3^-^ IL7R^+^ Cells From IBD Patients {#sec2.4}
---------------------------------------------------------------------------------------------

Our preclinical data support the possibility that targeting IL6 may be therapeutically tractable in chronic gut inflammation. Therefore, we aimed to verify whether this pathway was relevant in human disease. As expected, stimulation of unfractionated intestinal immune cells with PMA and ionomycin resulted in production of pathogenic cytokines, including IL17A, IL22, and interferon-γ by CD3^+^ T cells ([Figure 5](#fig5){ref-type="fig"}*A* and [Supplementary Figure 6](#figS6){ref-type="fig"}*A*). However, we also observed production of these cytokines in the non--T-cell (CD3^-^) fraction, particularly in IBD patients. Within the non--T-cell fraction (CD3^-^), we could identify a population of IL7R-expressing cells in the colon of patients with CD, UC, and noninflammatory control patients ([Figure 5](#fig5){ref-type="fig"}*B*). Although the frequency of these cells was variable, their proportional abundance within the lymphocyte population was increased in IBD patients in comparison with noninflammatory controls ([Figure 5](#fig5){ref-type="fig"}*B*). Consistent with ILC3s being present among the CD3^-^ IL7R^+^ population, there was enriched expression of RORγt and c-kit (CD117) ([Figure 5](#fig5){ref-type="fig"}*C* and [Supplementary Figure 6](#figS6){ref-type="fig"}*C*). *RORC* transcripts also were enriched in fluorescence-activated cell sorter--purified CD3^-^ IL7R^+^ cells analyzed by real-time PCR ([Supplementary Figure 6](#figS6){ref-type="fig"}*B*), corroborating the likelihood of ILCs being present in the CD3^-^ IL7R^+^ population. Analysis of the CD3^-^ IL7R^+^ population according to NCR expression showed the presence of 3 discrete populations, comprising NKp46^+^ NKp44^-^ cells, NKp44^+^ NKp46^-^ cells, and NCR^-^ (NKp44^-^ NKp46^-^) cells ([Figure 5](#fig5){ref-type="fig"}*D* and [Supplementary Figure 6](#figS6){ref-type="fig"}*C*), indicating that NCR^+^ and NCR^-^ ILCs are present within this CD3^-^ IL7R^+^ population. In most patients, including IBD and noninflammatory control patients, CD3^-^ IL7R^+^ NKp44^+^ NKp46^-^ cells were the predominant subset present ([Figure 5](#fig5){ref-type="fig"}*D* and [Supplementary Figure 6](#figS6){ref-type="fig"}*C*).

To determine whether CD3^-^ IL7R^+^ cells present in diseased mucosa of IBD patients were responsive to IL6, cLPMCs were incubated overnight with recombinant human IL6 before being restimulated with PMA and ionomycin. Production of IL17A, IL22, and interferon-γ by CD3^-^ IL7R^+^ cells was increased significantly when cLPMCs were cultured in the presence of IL6 ([Figure 6](#fig6){ref-type="fig"}*A* and *B*). In addition, some samples were stimulated with IL6 directly without mitogen, which showed induction of IL17A by CD3^-^ IL7R^+^ cells in a dose-dependent manner ([Figure 6](#fig6){ref-type="fig"}*C*).

Finally, we analyzed IL6 production by diseased mucosa from IBD patients to see whether blocking IL6 might be a reasonable therapeutic strategy in some or all IBD patients. IL6 was produced by colon explant cultures in CD, UC, and noninflammatory control patients ([Supplementary Figure 6](#figS6){ref-type="fig"}*D*). However, IL6 production was variable, especially in IBD patients, ranging from 72.2 to 8426.4 pg/mg colonic tissue. IBD patients could be stratified according to mucosal production of IL6, with half of IBD patients producing relatively low levels comparable with noninflammatory control patients and the other half producing high amounts (\>1000 pg/mg tissue). Taken together, these data indicate that IL6, which is produced in very high quantities in approximately 50% of CD and UC patients drives pathologically relevant immune pathways in chronic intestinal inflammation.

Discussion {#sec3}
==========

CD4^-^ NCR^-^ ILC3s are the predominant CD90^+^ IL7R^+^ ILC population in the colon of TRUC mice responsible for causing disease. Purified intestinal NCR^-^ ILC3 from TRUC mice produced IL17A and IL22, but were poor producers of interferon-γ and tumor necrosis factor α. They were also a modest source of IL6. Few NCR^+^ ILCs were present in the colon of TRUC mice, consistent with data from other groups reporting a requirement for T-bet in NKp46^+^ ILC development and differentiation.[@bib22] Intestinal CD4^+^ ILCs are important in host resistance to intestinal pathogens, such as *Citrobacter rodentium*.[@bib5] Here, we show that CD4^+^ ILCs, which are abundant in mLN, but infrequent in the colon, do not play a major role in TRUC disease. Depletion of CD4^+^ ILCs had no impact on pathogenic cytokine production or disease outcome.

In TRUC mice, highly purified colonic NCR^-^ ILC3 did not respond to IL23 or IL1α in isolation. Instead, combinations of IL23 together with IL1α were required for production of effector cytokines by ILC3. Furthermore, additional exposure to IL6 was required for optimal IL17A and IL22 production, showing a novel role for IL6 in the innate immune system in chronic intestinal inflammation.

IL17A-, IL22-, and interferon-γ--producing CD3^-^ IL7R^+^ cells also were identified in the colonic lamina propria of patients with IBD. Although this population is heterogeneous, there was enrichment of RORγt and c-kit, confirming the likelihood that ILC3 were present within this compartment. Most CD3^-^ IL7R^+^ cells were NKp44^+^, although NKp46^+^ and NCR^-^ (NKp44^-^ NKp46^-^) cells also were present. These data are broadly consistent with previous reports of ILC populations in human gut.[@bib12; @bib13; @bib14] Crucially, IL6 increased pathogenic cytokine production by CD3^-^ IL7R^+^ cLPMCs from IBD patients in a dose-dependent manner, consistent with our preclinical data showing IL6-responsive colonic ILC3s.

IL6 is a pleiotropic cytokine that may be important in IBD. Peripheral blood and cLPMCs produce excess IL6 in IBD,[@bib23; @bib24] often at levels correlating with disease activity.[@bib25] Genetic variation at the *IL6* locus is linked with early onset IBD[@bib26] and polymorphisms at loci encoding IL6R signaling components are associated with increased IBD risk.[@bib3] IL6 blockade is therapeutic in some preclinical models of IBD, although it has been assumed that the therapeutic mechanism likely was attributable to limitation of T-cell--mediated pathology[@bib27; @bib28; @bib29; @bib30] because IL6 contributes to intestinal Th17 differentiation.[@bib31] We show a novel role of IL6 in innate immune-mediated chronic intestinal pathology. It is interesting that cytokines contributing to CD4^+^ Th17 differentiation, including IL1, IL23, and IL6, have conserved roles promoting innate IL17 production. Our data build on other work implicating ILCs as potentially important mediators in IBD,[@bib12; @bib13; @bib14] and confirm NCR^-^ ILC3 as a source of pathogenic cytokines in IBD. Polymorphisms at multiple susceptibility loci in IBD that previously were considered to impact adaptive immunity, similarly could impact ILC phenotype, including *RORC*, *IL23R*, *IL12RB2*, *IL12B*, *IL22*, *IFNG*, *STAT1*, *STAT3*, *STAT4*, *CCR6*, *IL1R1*, *IL15RA*, and *IL6ST*.[@bib3] Accordingly, it is possible that genetic variation at these loci in IBD could impact disease susceptibility by altering the activation and effector function of mucosal ILCs. However, the relative contribution of ILC to the initiation and propagation of chronic intestinal inflammation in IBD remains to be determined. Polyclonal stimulus of unfractionated cLPMCs from IBD patients showed that most cytokine-expressing cells reside within the CD3^+^ cell fraction. It should be remembered that cytokine responses induced by polyclonal stimuli may overestimate T-cell contribution because under physiological conditions few of these tissue-trafficking T cells would be encountering their relevant antigen, so would unlikely be triggered to produce cytokine. By contrast, despite their numeric inferiority to T cells, mucosal ILC are likely to be activated directly by cytokine signals abundant in chronically inflamed tissue, such as IL6. IL6-induced stimulation of ILC effector function may prove to be especially pertinent in UC because IL23, the canonical ILC-activating cytokine, is produced at low levels in UC in comparison with CD.[@bib32]

In this study, IL6 neutralization reduced innate production of IL17A in TRUC mice and significantly attenuated disease severity, although the magnitude of impact was less than seen with ILC depletion or IL23 blockade.[@bib7] This is in keeping with our observation that although IL6 is required for optimal activation of ILC effector function, other proximal cytokine signals, including IL23 and/or IL1 stimulation, additionally are required. IL6 blockade had a minimal impact on the intestinal microbiota, other than a minor shift in the proportional abundance of Firmicutes and a tendency for increased intestinal bacterial diversity. It is possible that this latter change occurred secondary to reduced intestinal inflammation in anti-IL6--treated mice. Indeed, IBD activity/severity is recognized to correlate inversely with bacterial diversity in the gut.[@bib33; @bib34]

Our data support extending biological therapies targeting IL6 in IBD. The IL6R blocking antibody tocilizumab is efficacious in other inflammatory diseases, including arthritis[@bib35; @bib36] and lupus,[@bib37] and a pilot study in CD showed promising initial results.[@bib38] In this study mucosal IL6 production was highly variable, however, only half of IBD patients produced more IL6 than non-IBD control patients. Similarly, the frequency of CD3^-^ IL7R^+^ cells, and the magnitude of IL6-induced cytokine responses by these cells also markedly was variable. With the promise of personalized medicine on the horizon,[@bib39] it is tempting to speculate that treatment strategies targeting IL6 might be favored in patient subsets defined by high mucosal expression of IL6 and/or high frequencies of IL6 responsive effector cells in diseased tissue.

In summary, we have shown that IL6 augments pathogenic cytokine production by intestinal ILCs in chronic intestinal inflammation and that this pathway may be operational in human IBD. Novel therapeutic strategies targeting ILC or their proximal cytokine signals may offer a new treatment paradigm in IBD.

Supplementary Materials and Methods {#appsec1}
===================================

Microbiota Analysis {#appsec1.1}
-------------------

DNA was extracted from mouse fecal samples using the FastDNA SPIN Kit for Soil and a FastPrep 24 machine (MP Biomedicals Santa Ana, CA) according to the protocol provided by the manufacturer. Bacterial 16S ribosomal RNA genes were PCR-amplified using barcoded primers MiSeq 27F (5'AATGATACGGCGACCACCGAGATCTACACTATGGTAATTCCAGMGTTYGATYMTGGCTCAG-3') and MiSeq-338R (5'-CAAGCAGAAGACGGCATACGAGAT-barcode-AGTCAGTCAGAAGCTGCCTCCCGTAGGAGT-3'), which target variable regions V1--V2 of the 16S ribosomal RNA gene. Q5 Taq polymerase (New England Biolabs, Ipswich, MA) was used for the PCR step, and 4 PCR reactions were performed per sample. Cycling conditions were as follows: 98°C for 2 minutes, followed by 20 cycles of 98°C for 30 seconds, 50°C for 30 seconds, 72°C for 90 seconds, and then a final extension step at 72°C for 5 minutes.

The 4 PCR reactions from each DNA extraction then were pooled and concentrated down to 25 μL volumes per sample. PCR amplicons then were quantified using a Qubit 2.0 Fluorometer (Life Technologies, Ltd, Carlsbad, CA) and equimolar concentrations of each were added to a final mastermix for sequencing, using an Illumina MiSeq (San Diego, CA) machine with 2 × 250 bp read length. Sequence data have been deposited in the European Nucleotide Archive under Study Accession Number ERP005850 and Sample Accession numbers ERS459682--ERS459702.

The sequence data were processed by following the MiSeq SOP of the mothur software package (Available at: <http://www.mothur.org/wiki/MiSeq_SOP>).[@bib40] Paired-read contigs were created from the forward and reverse read sequence data, and preliminary quality processing was performed by removing all contigs that were shorter than 260 bp, longer than 450 bp, or those that contained any ambiguous bases or homopolymeric stretches longer than 7 bases. Perseus,[@bib41] as implemented in mothur, was used to remove putative chimeras, and any reads mapping to chloroplasts, mitochondria, eukarya, or archaea also were removed. After these steps, more than 486,000 sequences were left in the final data set (range, 447--51,571 sequences per sample). Next, after a preclustering step (diffs, 3), 97% similarity OTUs were generated. Taxonomic classifications for each of these OTUs were created using the RDP taxonomy provided at the mothur web page. Metastats,[@bib42] as implemented in mothur, was used to test for significant differences in the proportional abundance of each of the phyla present, and the 150 most abundant OTUs between anti-IL6 and control mice. Bacterial diversity was measured by generating Shannon and inverse Simpson indices in mothur. Before these calculations each sample was subsampled randomly down to 447 reads to ensure equal sequencing depth for each. Kruskall--Wallis and Mann--Whitney U tests, implemented in Minitab v16, were used to test for significant differences in diversity measures between the anti-IL6 and control mouse groups. A cluster dendrogram, using the Bray Curtis calculator, also was generated in mothur from the subsampled data set, and subsequently was visualized using the iTOL online software resource.[@bib43]Supplementary Table 1Flow Cytometry Antibodies UsedAntigenCloneSupplierAnti-mouse antibodies CD4530-F11eBioscience CD90.253-2.1eBioscience CD127A7R34eBioscience NKp4629A1.4eBioscience CD126D7715A7Biolegend CCR6140706R&D Systems ICOS7E.17G9eBioscience CD4RM4.5eBioscience Hematopoietic lineage cocktail (CD3, CD45R, B220, CD11b, TER-119, Gr-1)17A2, RA3-6B2, M1/70, TER-119eBioscience CD62LMEL-14eBioscience IL17RB752101R&D Systems CD69H1.2F3eBioscience RORγtAFKJS-9eBioscience IL17AeBio17B7eBioscience IL221H8PWSReBioscience Interferon-γXMG1.2eBioscience IL411B11eBioscienceAnti-human antibodies CD3UCHT-1Biolegend CD127A019D5 (eBioRDR5)Biolegend (eBioscience) CD117104D2eBioscience NKp469E2eBioscience NKp4444.189eBioscience IL17RBI170220R&D Systems RORγtAFKJS-9eBioscience IL17AeBio64DEC17eBioscience IL2222URTIeBioscience Interferon-γ4S.B3eBioscienceSupplementary Table 2Metastats Comparison Between the Proportional Abundance of the Top 150 Most Abundant OTUs in the Microbiota Data Set Between Anti-IL6 and Control Mice GroupsOTU no.RDP taxonomic classificationsNCBI MegaBLAST ID*P* valueQ valuePhylumClassOrderFamilyGenusOtu0001Firmicutes(100)Bacilli(100)Lactobacillales(100)Lactobacillaceae(100)Lactobacillus(100)*Lactobacillus animalis*/*murinus*.2875951Otu0002Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)unclassified(100)*Butyrivibrio* species P79 (86% similarity).0223761Otu0003Firmicutes(100)Bacilli(100)Lactobacillales(100)Lactobacillaceae(100)Lactobacillus(100)*Lactobacillus taiwanensis*/*johnsonii*/*acidophilus*.9474841Otu0004Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Clostridium_XlVb(100)*Clostridium lactatifermentans* (90% similarity).153431Otu0005Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100)*Eubacterium plexicaudatum* (92% similarity).820041Otu0006Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Unclassified(100)Unclassified(100)*Butyricimonas* species JCM 18677 (80% similarity).0121821Otu0007Proteobacteria(100)Epsilonproteobacteria(100)Campylobacterales(100)Helicobacteraceae(100)Helicobacter(100)*Helicobacter typhlonius*.1738891Otu0008Deferribacteres(100)Deferribacteres(100)Deferribacterales(100)Deferribacteraceae(100)Mucispirillum(100)*Mucispirillum colimuris*.0633651Otu0009Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Rikenellaceae(100)Alistipes(100)*Alistipes onderdonkii* (90% similarity).8740141Otu0010Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Rikenellaceae(100)Alistipes(100)*Alistipes senegalensis* (91% similarity).8007811Otu0011Firmicutes(100)Clostridia(100)Clostridiales(100)Unclassified(100)Unclassified(100)*Clostridium scindens* (88% similarity).7662191Otu0012Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100)*Coprococcus catus* (88% similarity).5716871Otu0013Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100)*Oscillibacter valericigenes* (91% similarity).031551Otu0014Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Bacteroidaceae(100)Bacteroides(100)*Bacteroides acidofaciens*/*uniformis*.0820541Otu0015Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Anaerotruncus(100)*Anaerotruncus colihominis* (92% similarity).4890231Otu0016Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100)*Clostridium hathewayi* (92% similarity).8619231Otu0017Firmicutes(100)Bacilli(100)Lactobacillales(100)Lactobacillaceae(100)Lactobacillus(100)*Lactobacillus reuteri*.6447461Otu0018Proteobacteria(100)Deltaproteobacteria(100)Unclassified(100)Unclassified(100)Unclassified(100)*Desulfocurvus vexinensis* (87% similarity).444671Otu0019Deferribacteres(100)Deferribacteres(100)Deferribacterales(100)Deferribacteraceae(100)Mucispirillum(100)*Mucispirillum colimuris* (97% similarity).0396721Otu0020Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Unclassified(99)Unclassified(99)*Tannerella forsythensis* (82% similarity).2626521Otu0021Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Bacteroidaceae(100)Bacteroides(100)*Bacteroides acidifaciens*.7337861Otu0022Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Prevotellaceae(100)Paraprevotella(100)*Prevotella species* (87% similarity).1372081Otu0023Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(52)Unclassified(52)*Coprococcus catus* (84% similarity).5012021Otu0024Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100)*Pseudobutyrivibrio ruminis* (88% similarity).5101851Otu0025Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Porphyromonadaceae(100)Paludibacter(77)*Prevotella dentalis* (81% similarity).1624841Otu0026Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Bacteroidaceae(100)Bacteroides(100)*Bacteroides uniformis* (96% similarity).1952791Otu0027Firmicutes(100)Erysipelotrichia(99)Erysipelotrichales(99)Erysipelotrichaceae(99)Erysipelotrichaceae_incertae_sedis(99)*Eubacterium cylindroides* (88% similarity).6052051Otu0028Firmicutes(100)Clostridia(100)Clostridiales(100)Unclassified(100)Unclassified(100)*Clostridium aminophilum* (86% similarity).2467691Otu0029TM7(100)TM7_class_incertae_sedis(100)TM7_order_incertae_sedis(100)TM7_family_incertae_sedis(100)TM7_genus_incertae_sedis(100)TM7 phylum species (93% similarity).2227011Otu0030Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100)*Clostridium phytofermentans* (90% similarity).5743961Otu0031Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100)*Clostridium celerecrescens* (93% similarity).6640061Otu0032Firmicutes(100)Clostridia(100)Clostridiales(100)Unclassified(100)Unclassified(100)*Clostridium scindens* (84% similarity).7372311Otu0033Proteobacteria(100)Gammaproteobacteria(100)Enterobacteriales(100)Enterobacteriaceae(100)Unclassified*Escherichia*/*Enterobacter*/*Citrobacter*/*Shigella* species.4975011Otu0034Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Rikenellaceae(100)Alistipes(100)*Alistipes senegalensis* (92% similarity).1273021Otu0035Firmicutes(100)Unclassified(100)Unclassified(100)Unclassified(100)Unclassified(100)Segmented filamentous bacterium.7983421Otu0036Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100)*Eubacterium oxidoreducens* (87%).3340681Otu0037Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100).2637091Otu0038Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Unclassified(100)Unclassified(100).9517011Otu0039Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Bacteroidaceae(100)Bacteroides(100).1781051Otu0040Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Lachnospiracea_incertae_sedis(79).9875981Otu0041Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100).9482991Otu0042Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Bacteroidaceae(100)Bacteroides(100).3341481Otu0043Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Dorea(93).8505981Otu0044Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Anaerotruncus(100).6222081Otu0045Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).9488491Otu0046Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Rikenellaceae(100)Alistipes(100).2110711Otu0047Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Clostridium_XlVb(100).4492051Otu0048Firmicutes(100)Clostridia(100)Clostridiales(100)Unclassified(100)Unclassified(100).1012191Otu0049Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Butyricicoccus(100).5977611Otu0050Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Porphyromonadaceae(100)Odoribacter(100).8248461Otu0051Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(72).8890061Otu0052Bacteroidetes(100)Unclassified(99)Unclassified(99)Unclassified(99)Unclassified(99).3528351Otu0053Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).4207491Otu0054Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100).8071541Otu0055Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Roseburia(100).5492081Otu0056Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)unclassified(100).7956951Otu0057Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Acetanaerobacterium(100).7955441Otu0058Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).5949231Otu0059Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).3194841Otu0060Firmicutes(100)Unclassified(100)Unclassified(100)Unclassified(100)Unclassified(100).8154761Otu0061Firmicutes(100)Clostridia(100)Clostridiales(100)Unclassified(100)Unclassified(100).2456781Otu0062Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Roseburia(100).6427521Otu0063Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).8662481Otu0064Firmicutes(100)Clostridia(100)Clostridiales(100)Unclassified(100)Unclassified(100).6843051Otu0065Actinobacteria(100)Actinobacteria(100)Coriobacteriales(100)Coriobacteriaceae(100)Enterorhabdus(100).4700261Otu0066Firmicutes(100)Unclassified(100)Unclassified(100)Unclassified(100)Unclassified(100).7814421Otu0067Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).0754251Otu0068Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).236041Otu0069Proteobacteria(100)Deltaproteobacteria(100)Desulfovibrionales(100)Desulfovibrionaceae(100)Desulfovibrio(93).1222821Otu0070Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Dorea(100).3357551Otu0071Firmicutes(100)Unclassified(100)Unclassified(100)Unclassified(100)Unclassified(100).2755641Otu0072Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Porphyromonadaceae(100)Unclassified(100).67591Otu0073Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(98)Unclassified(98).7390091Otu0074Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100).0996381Otu0075Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Porphyromonadaceae(100)Unclassified(100).1422591Otu0076Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).4463791Otu0077Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Butyrivibrio(91).0481251Otu0078Actinobacteria(100)Actinobacteria(100)Coriobacteriales(100)Coriobacteriaceae(100)Unclassified(100).0200511Otu0079Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).9953361Otu0080Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Dorea(100).5809091Otu0081Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Butyrivibrio(96).2311311Otu0082Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).1447521Otu0083Actinobacteria(100)Actinobacteria(100)Coriobacteriales(100)Coriobacteriaceae(100)Asaccharobacter(100).6837321Otu0084Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).0595981Otu0085Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Anaerotruncus(100).5577241Otu0086Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Anaerotruncus(100).8292961Otu0087Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Unclassified(100).1476041Otu0088Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).3251881Otu0089Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).2703531Otu0090Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Clostridium_XlVa(98).8936071Otu0091Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Unclassified(97)Unclassified(97).0647461Otu0092Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Syntrophococcus(100).4657831Otu0093Proteobacteria(100)Deltaproteobacteria(100)Desulfovibrionales(100)Desulfovibrionaceae(100)Desulfocurvus(73).7191971Otu0094Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Pseudoflavonifractor(100).2239231Otu0095Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Pseudoflavonifractor(65).3236151Otu0096Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).2204021Otu0097Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).7555241Otu0098Firmicutes(100)Erysipelotrichia(100)Erysipelotrichales(100)Erysipelotrichaceae(100)Clostridium_XVIII(100).1679661Otu0099Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).6589521Otu0100Firmicutes(100)Bacilli(100)Lactobacillales(100)Streptococcaceae(100)Streptococcus(100).2715561Otu0101Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100).5299121Otu0102Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Unclassified(98).2396921Otu0103Actinobacteria(100)Actinobacteria(100)Coriobacteriales(100)Coriobacteriaceae(100)Unclassified(100).4386921Otu0104Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Flavonifractor(97).8842991Otu0105Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Porphyromonadaceae(100)Parabacteroides(100).6041511Otu0106Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).0528351Otu0107Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Lactonifactor(100).6883851Otu0108Firmicutes(100)Unclassified(100)Unclassified(100)Unclassified(100)Unclassified(100).8084441Otu0109Unclassified(100)Unclassified(100)Unclassified(100)Unclassified(100)Unclassified(100).5809631Otu0110Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Rikenellaceae(100)Alistipes(100).5905561Otu0111Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).707021Otu0112Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Anaerotruncus(100).6293851Otu0113Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Clostridium_XlVa(97).6909151Otu0114Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100).6598521Otu0115Firmicutes(100)Clostridia(100)Clostridiales(100)Unclassified(100)Unclassified(100).0520711Otu0116Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Clostridium_IV(100).4967491Otu0117Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Lachnospiracea_incertae_sedis(64).7830831Otu0118Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).4502171Otu0119Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Anaerotruncus(100).4747661Otu0120Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Roseburia(100).6775781Otu0121Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Pseudoflavonifractor(100).7648181Otu0122Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Roseburia(71).2215751Otu0123Proteobacteria(100)Deltaproteobacteria(100)Desulfovibrionales(100)Desulfovibrionaceae(100)Bilophila(100).7596011Otu0124Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Hydrogenoanaerobacterium(100).6414791Otu0125Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Pseudoflavonifractor(100).0156581Otu0126Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Flavonifractor(100).0175471Otu0127Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Butyrivibrio(100).1062341Otu0128Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100).0907691Otu0129Firmicutes(100)Erysipelotrichia(100)Erysipelotrichales(100)Erysipelotrichaceae(100)Erysipelotrichaceae_incertae_sedis(100).3049721Otu0130Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Syntrophococcus(100).3513361Otu0131Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Flavonifractor(100).7331341Otu0132Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Pseudoflavonifractor(100).6514591Otu0133Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100).3362191Otu0134Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Rikenellaceae(100)Alistipes(100).3644531Otu0135Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).2970571Otu0136Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Anaerotruncus(100).2552341Otu0137Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(66).065941Otu0138Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Clostridium_XlVa(100).9348831Otu0139Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Porphyromonadaceae(100)Unclassified(100).3644531Otu0140Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).0192221Otu0141Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).4860031Otu0142Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).7143991Otu0143Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).6416891Otu0144Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Porphyromonadaceae(69)Unclassified(69).5118261Otu0145Bacteroidetes(100)Flavobacteria(97)Flavobacteriales(97)Unclassified(97)Unclassified(97).7183421Otu0146Bacteroidetes(100)Bacteroidia(100)Bacteroidales(100)Rikenellaceae(100)Alistipes(100).9774931Otu0147Firmicutes(100)Clostridia(100)Clostridiales(100)Ruminococcaceae(100)Oscillibacter(100).3457781Otu0148Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).088331Otu0149Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Clostridium_XlVb(100).5487811Otu0150Firmicutes(100)Clostridia(100)Clostridiales(100)Lachnospiraceae(100)Unclassified(100).6335381[^1]Supplementary Figure 1(*A*) Representative flow cytometry plot and statistical analysis (*B*) showing differential expression of NKp46 and CCR6 in live CD45^+^ CD90^+^ IL7R^+^ cells in the colon of *Rag2*^-/-^ (n = 6, *white bar*) and TRUC (n = 5, *red bar*) mice. *Error bars* depict SEM. \**P* \< .01, \*\**P* \< .005. (*C*) Flow cytometric analysis of the phenotype of CD90^+^ IL7R^+^ ILCs in the colons of TRUC mice. *Grey histograms* show staining with isotype-matched control antibody in comparison with staining with specific antibody (*white histograms with black lines*). Data are representative of more than 3 individual experiments. (*D*) Proportion of cytokine-expressing CD45^+^ CD90^+^ IL7R^+^ ILCs in the colons of *Rag2*^-/-^ and TRUC mice after stimulation of unfractionated cLPMCs with PMA and ionomycin. Each *dot/square* represents an individual mouse.Supplementary Figure 2(*A*) IL6 concentration in serum (*left panel*) and colon explant culture (*right panel*) of *Rag2*^-/-^ and TRUC mice measured by ELISA. *Dots/squares* represent individual mice. *Line* depicts the median. (*B*) Microarray analysis showing abundance of transcripts encoded by genes known to be regulated by IL6 in the colon of TRUC mice relative to *Rag2*^-/-^ mice. *Blue bars* represent transcripts up-regulated in the colons of TRUC mice and *red bars* represent down-regulated genes (in comparison with *Rag2*^-/-^ mice).Supplementary Figure 3(*A*) FACs gating strategy used to purify ILCs from the colon of TRUC mice. CD45^+^ cells were first enriched from cLPMCs using anti-CD45 immunomagnetic beads. ILCs were FACs purified more than 98%. (*B*) Cytokine production by FACs purified CD90^+^ IL7R^+^ NKp46^-^ colonic ILCs from TRUC mice. Cells were cultured in the presence of combinations of IL1α, IL23, IL6 (as depicted), or medium alone (unstimulated). IL6 was measured in culture supernatant by CBA. *Bars* show the mean cytokine production and *error bars* depict the SEM. Data are from 2 independent experiments.Supplementary Figure 4(*A*) Flow cytometry plots showing IL6R expression by CD4^+^ T cells, ILCs (lineage^-^ IL7R^+^) in the colons of wild-type (WT) and TRUC mice. Data are representative of 3 independent experiments. (*B*) Concentration of sIL6R in serum (n = 6) and supernatants of cultured colon explants (n = 5) and unfractionated splenocytes (n = 3) measured by ELISA. *Bars* represent the mean sIL6R concentration and *error bars* depict the SEM.Supplementary Figure 5(*A*) Concentration of IL6 in serum of TRUC mice treated with anti-IL6 or control isotype antibody. *Dots/squares* represent individual mice. *Line* depicts median. (*B*) Bray Curtis cluster dendrogram showing that anti-IL6 treatment is not associated with a distinct microbiota profile. "Pre" indicates samples before anti-IL6 treatment and "Post" indicates samples after treatment. Bacterial families colored in shades of green belong to the Firmicutes phylum, blue belong to the Bacteroidetes phylum, yellow belong to the Deferribacteres phylum (*Mucispirillum* genus), and maroon/red belong to the Proteobacteria phylum. (*C*) *Box* and *whisker plots* of Simpson diversity index of the intestinal microbiota from TRUC mice treated with anti-IL6 or isotype-matched control antibodies. Diversity indices are highly sensitive to differential sequencing depth. Therefore, analyses were confined to 477 reads per sample.Supplementary Figure 6(*A*) Representative flow cytometry plots of intracellular cytokine and surface CD3 expression in noninflammatory control, CD, and UC patients. Cells were stimulated with PMA and ionomycin. (*B*) Real-time PCR analysis of *RORC* expression in sorted colonic CD3^-^ IL7R^+^ cells in comparison with CD14^+^ monocytes (immunomagnetically selected from peripheral blood monocytes). Histogram shows the mean expression of *RORC* in purified colonic CD3^-^ IL7R^+^ cells (n = 2 IBD patients) relative to monocytes. (*C*) Proportion of colonic CD3^-^ IL7R^+^ cells expressing c-kit (CD117) in noninflammatory control, CD, and UC patients. (*D*) Proportion of colonic CD3^-^ IL7R^+^ cells expressing NKp46, NKp44, or double-negative cells (NKp46^-^ NKp44^-^) in noninflammatory control, CD, and UC patients. (*E*) IL6 production in colon explant cultures from IBD patients. In graphs, each *dot* represents an individual patient and a *line* depicts the median.

The authors are grateful to the Wellcome Trust Sanger Institute's core sequencing team for performing 16S ribosomal RNA gene sequencing, and to Chris Evagora and support staff at the Pathology Core at Queen Mary University of London.

Microbiota sequence data were deposited in the European Nucleotide Archive under Study Accession Number ERP005850 and Sample Accession Numbers ERS459682--ERS459702.

**Conflicts of interest** These authors disclose the following: Nick Powell has received honoraria for acting in an advisory capacity or speaking on behalf of Actavis UK, Ferring and AstraZeneca; Peter Irving has received honoraria for acting in an advisory capacity or speaking on behalf of AbbVie, MSD, Actavis UK, Shire, Ferring, Falk, Genentech, Tillotts, Takeda, Vifor Pharma, Pharmacosmos, and Symprove; Thomas MacDonald receives support from Glaxo Smith Kline, Janssen Pharmaceuticals, Grunenthal, VH2, and Topivert; and Bu Hayee has received honoraria for acting in an advisory capacity or speaking on behalf of AbbVie, Takeda, and Actavis UK. The remaining authors disclose no conflicts.

**Funding** Supported by grants awarded from the Wellcome Trust (WT101159AIA to N.P.; WT088747MA to N.P., G.M.L., and T.T.M.; 091009 to G.M.L.; and 098051 to A.W.W., P.S., and J.P.), and the Medical Research Council (G0802068 to G.M.L. and T.T.M., and MR/K002996/1 to G.M.L. and J.K.H.), by the Scottish Government Rural and Environmental Science and Analysis Service (A.W.W.), and by the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' and King's College London. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at [www.gastrojournal.org](http://www.gastrojournal.org){#intref0010}, and at <http://dx.doi.org/10.1053/j.gastro.2015.04.017>.

![IL17A/IL22-producing CD4^-^ NCR^-^ ILC3 mediate colitis in TRUC mice. (*A*) Flow cytometry dot plots of live, CD45^+^ cells according to expression of CD90 and IL7R in the colons of *Rag2*^-/-^ and TRUC mice, and (*B*) absolute numbers of live CD45^+^ CD90^+^ IL7R^+^ ILCs in the colons of TRUC and *Rag2*^-/-^ mice. Each *dot/square* represents an individual mouse. *Line* depicts the median. (*C*) Representative flow cytometry dot plots (*left*) and statistical analysis (*right*) of the proportion of CD4^+^ and CD90^+^ cells (gated on live CD45^+^ cells) in mLNs and colons of TRUC mice treated with isotype-matched control antibodies (n = 5), anti-CD4 (n = 4), or anti-CD90 (n = 4) antibodies. Statistical analyses were performed on colonic cells and show the proportion of colonic ILCs (cILCs) after treatment. \**P* \< .019, \*\**P* \< .04. (*D*) Representative flow cytometry dot plots (*left*) and statistical analysis (*right*) of the proportion of IL17A^+^ and IL22^+^ cells (gated on live CD45^+^ cells) in the colon of TRUC mice treated with isotype-matched control antibodies (n = 5), anti-CD4 (n = 4), or anti-CD90 (n = 24) antibodies. Cells were stimulated with PMA and ionomycin before intracellular cytokine staining \**P* \< .01. (*E*) Representative colon micrographs (H&E stained) (*left*) and statistical analysis of colitis scores (*right*) of TRUC mice treated with isotype-matched control antibodies, anti-CD4, or anti-CD90 antibodies. \**P* \< .03 (for both anti-CD90 vs control antibody and anti-CD90 vs anti-CD4). Each *dot/square* represents an individual mouse. *Lines* depict the median.](gr1){#fig1}

![IL6 promotes cytokine production by NCR^-^ ILC3s in a cell-intrinsic manner. (*A*) Microarray analysis showing an abundance of cytokine transcripts in the colon of TRUC mice relative to *Rag2*^-/-^ mice. *Blue dotted line* depicts 2-fold induction. (*B*) IL17A production by unfractionated cLPMCs and mLN cells isolated from TRUC mice in medium alone (-) or after supplementation with recombinant IL6 or IL23. *Columns* represent mean cytokines and *error bars* depict SEM. Analysis of cLPMCs comprised 4 biological replicates. Analysis of mLN included 9 biological replicates for the unstimulated condition and 7 biological replicates for each of the stimulated conditions. \**P* \< .02; \*\**P* \< .003. (*C*) Flow cytometry plots of intracellular IL17A expression by CD90^+^ NKp46^-^ cells after stimulation of unfractionated mLN cells with IL6, IL23, or unstimulated cells (-), which were incubated with monensin alone. Data are representative of 3 separate experiments. (*D*) Cytokine production by fluorescence-activated cell sorted CD45^+^ CD90^+^ IL7R^+^ NKp46^-^ ILCs purified from the colons of TRUC mice (the gating strategy for cell sorting is illustrated in [Supplementary Figure 3](#figS3){ref-type="fig"}*A*). Purified NCR^-^ ILCs were stimulated with combinations of IL1α, IL6, and IL23 as depicted. After 24 hours cytokine concentrations were measured in culture supernatant by ELISA or CBA. Data are representative of 2 individual experiments with ILCs pooled from 10--15 colons. *Bars* show the mean cytokine production and *error bars* depict SEM.](gr2){#fig2}

![IL6 blockade reduces IL17A production and attenuates TRUC disease. (*A*) IL17A concentration in culture supernatants of unfractionated cLPMCs and splenocytes from TRUC mice treated with anti-IL6 (n = 8) or isotype-matched control antibodies (n = 8). (*B*) Representative colon micrographs (H&E stained) (*left panel*) and statistical analysis (*right panel*) of colitis scores of distal colons of TRUC mice treated with anti-IL6 or isotype-matched control antibodies. (*C*) Spleen and colon mass of TRUC mice treated with anti-IL6 or isotype-matched control antibodies. Each *dot/square* represents an individual mouse. *Lines* represent medians. Results from 2 separate antibody blockade experiments conducted under the same experimental conditions were pooled.](gr3){#fig3}

![IL6 blockade does not significantly impact the composition of the intestinal microbiota in TRUC mice. (*A*) The mean percentage of sequences of particular phyla present in the intestinal microbiota of TRUC mice before (*top panel*) and after (*bottom panel*) treatment with anti-IL6 (*red bars*) or isotype-matched control antibodies (*white bars*). (*B*) The mean proportional abundance of *H typhlonius* in the intestinal microbiota of TRUC mice before and after treatment with anti-IL6 (*red bars*) or isotype-matched control antibodies (*white bars*). Error bars depict the SEM.](gr4){#fig4}

![CD3^-^ IL7R^+^ cells are expanded in IBD patients. (*A*) Flow cytometry plots showing CD3 and intracellular IL17A expression in unfractionated cLPMCs after stimulation with PMA and ionomycin. Additional representative flow cytometry plots are illustrated in [Supplementary Figure 6](#figS6){ref-type="fig"}*A*. (*B*) Representative flow cytometry plots (*left panel*) and statistical analysis (*right panel*) of CD3 and IL7R staining by LPMCs in the colon of noninflammatory control and IBD patients. Individual *dots* represent individual patients. \**P* \< .04. (*C*) Flow cytometric analysis of the phenotype of colonic CD3^-^ IL7R^+^ cells. *Grey histograms* show isotype control antibody staining. *White histograms* show staining with specific antibody. Data are representative of more than 3 independent experiments in IBD patients. (*D*) Flow cytometry dot plots showing expression of NKp46 and NKp44 by colonic CD3^-^ IL7R^+^ cells in noninflammatory control and IBD patients. Further analyses of additional patient replicates are shown in [Supplementary Figure 6](#figS6){ref-type="fig"}*C* and *D*.](gr5){#fig5}

![IL6-responsive CD3^-^ IL7R^+^ cells are present in the colon of IBD patients. (*A*) Flow cytometry histograms and (*B*) statistical analyses of intracellular cytokine expression by CD3^-^ IL7R^+^ cells after overnight culture in the presence or absence of IL6 (100 ng/mL). Cells were restimulated with PMA and ionomycin before staining. (*B*) Each connected pair of *dots* represents an individual patient. (*C*) Flow cytometry histograms showing the number of CD3^-^ IL7R^+^ IL17A^+^ cells after culture with increasing doses of IL6.](gr6){#fig6}

[^1]: NOTE. Taxonomic classifications for each OTU were generated using the reference taxonomy database from the Ribosomal Database Project. The numbers in parenthesis following each classification show the consistency of the classification assignments (in percent) for all of the sequence reads within a given OTU. p values and q values (false discovery rate adjusted p values, to allow for multiple comparisons) were generated using Metastats software (White JR et al. PLoS Comput Biol. 2009:e1000352).
